Key facts
- It has raised $13.4M; the latest was Later Stage VC ($13.4M) in Apr 2025.
- Notable investors include Coalition for Epidemic Preparedness Innovations.
- Status: Privately Held (backing).
- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for Gennova
- ·The full record, as it builds
Funding rounds
No funding rounds for Gennova are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Gennova
Developer of a biotechnology platform designed to provide bio-manufacturing processes to develop safe, effective and affordable bio-therapeutics. The company's platform is dedicated to the development, production and commercialization of bio-therapeutics to tackle life-threatening diseases across various indications, enabling patients to recover faster from any type of deadly disease.
- Sector
- Healthcare
- HQ
- Pune, India
- Founded
- 2001
- Employees
- 606
- Website
- gennova.bio/
- Ownership
- Privately Held (backing)
Gennova doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Gennova shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Gennova in its N-PORT filings yet. We sweep new filings monthly.